Cycle Pharmaceuticals and Anovo Deliver Relief to Those with Homozygous Cystinuria
July 29, 2024
Cycle Pharmaceuticals was founded in 2012 with one mission in mind: delivering best-in-class drug treatments and services to the underserved rare disease patient community. With a focus on rare metabolic, immunological, and neurological genetic conditions, Cycle Pharmaceuticals primarily serves patients who require life-long treatments, such as those with homozygous cystinuria.
What is Homozygous cystinuria?
Homozygous cystinuria is a rare disease that affects approximately 1 in every 10,000 Americans. It is characterized by excessive amounts of undissolved cystine in the urine, which can lead to the formation of crystals and stones in the kidney, bladder, or urinary tract. Patients with cystinuria often experience initial symptoms such as frequent urinary tract infections, blood in the urine, and/or sharp pain in the side of the abdomen or lower back. If left untreated, the formation of kidney stones due to homozygous cystinuria can result in renal failure.
Cycle Pharmaceuticals Partners with Anovo
Anovo is excited to announce a new partnership with Cycle Pharmaceuticals to become the exclusive distributor and specialty pharmacy for Tiopronin, a revolutionary orphan drug licensed by Torrent Pharmaceuticals and used in the treatment of severe homozygous cystinuria. We’re confident in Tiopronin’s ability to change our patients’ lives and make a difference for those who suffer from kidney stones.
Related Posts
Investing in Training to Elevate Patient Care
At Anovo, we believe that exceptional patient support starts with a well-trained, knowledgeable team. As we continue to grow, we’ve…
April 1, 2025
Case Study: Transitioning Egetis Therapeutics’ Expanded Access Program to Anovo
As Egetis prepared for its first launch, it made the strategic decision to partner for the management of its Expanded…
March 28, 2025
How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 24, 2025
